General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Ipsen to acquire Epizyme, expanding its portfolio in oncology | globenewswire.com • |
Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022 | globenewswire.com • |
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology | globenewswire.com • |
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology | businesswire.com • |
Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y | zacks.com • |
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates | zacks.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2022-08-09 | 2022-06 | -0.36 | N/A | N/A | N/A |
2022-05-10 | 2022-03 | -0.35 | N/A | N/A | N/A |
2022-03-01 | 2021-12 | -0.41 | N/A | N/A | N/A |
2021-11-09 | 2021-09 | -0.45 | N/A | N/A | N/A |
2021-08-09 | 2021-06 | -0.6 | N/A | N/A | N/A |
2021-05-06 | 2021-03 | -0.56 | N/A | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2022-06-28 | Cowen & Co. | Downgrade | Outperform | Market Perform |
2022-06-27 | Wedbush | Downgrade | Outperform | Neutral |
2022-06-03 | HC Wainwright & Co. | Upgrade | Buy | |
2022-05-12 | HC Wainwright & Co. | Upgrade | Buy | |
2022-03-02 | HC Wainwright & Co. | Upgrade | Buy | |
2021-08-10 | Morgan Stanley | Downgrade | Equal-Weight | Underweight |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-08-08 | AGARWAL SHEFALI | Officer | 285.56K | Conversion of Exercise of derivative security |
2022-05-16 | BATE KENNETH M | Director | 17.05K | Stock Award(Grant) |
2022-08-08 | BEAULIEU JOSEPH | Officer | 51.10K | Conversion of Exercise of derivative security |
2022-06-29 | BEVERIDGE ROY A M.D. | Director | 46.04K | Stock Award(Grant) |
2022-08-08 | BOGLE GRANT C | Chief Executive Officer | 259.17K | Conversion of Exercise of derivative security |
2022-06-29 | CONROY KEVIN T | Director | 62.32K | Stock Award(Grant) |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-06-29 | RP Management, LLC | 31.84M | 46.81M | 18.91% |
2022-06-29 | Primecap Management Company | 16.64M | 24.46M | 9.88% |
2022-03-30 | Blackrock Inc. | 10.78M | 15.84M | 6.40% |
2022-06-29 | Vanguard Group, Inc. (The) | 7.54M | 11.08M | 4.48% |
2022-03-30 | Rock Springs Capital Management, LP | 7.27M | 10.68M | 4.32% |
2022-03-30 | Palo Alto Investors Lp | 6.77M | 9.96M | 4.02% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2022-06-29 | Primecap Odyssey Aggressive Growth Fund | 10.74M | 15.79M | 6.38% |
2022-06-29 | Primecap Odyssey Growth Fund | 4.82M | 7.09M | 2.86% |
2022-03-30 | Vanguard Total Stock Market Index Fund | 3.63M | 5.33M | 2.15% |
2022-05-30 | iShares Russell 2000 ETF | 3.02M | 4.43M | 1.79% |
2022-05-30 | Fidelity Select Portfolios - Biotechnology | 2.62M | 3.85M | 1.56% |
2022-03-30 | Vanguard Extended Market Index Fund | 2.52M | 3.70M | 1.50% |
Decision for acceptance to filing in Feb and PDUFA goal date would be Aug 18, 2020 for FL.
Scientifically very sound company. The low will attract Pharma companies to expand Oncology Portfolio. A new class of drug has evolved. This will be extended to other Indications as well. Hold for 6 months for your money to double. I will be adding after taking some profit of AIMT
Company is good in Science not in PR. Volume only 150k AH. Should improve now after seeking alpha reporting. Maybe even good tomorrow
Just 700 patients in US. But still has FollicularLymphoma indication for the same drug
Epithelial Sarcoma is a small indication
Are you guys on the call?
Are they getting an approval today or acceptance for filing?
$EPZM the RSI ismid 80’s causing it to be overbought and decline in price
$EPZM the presentation will include data from June 2019, that abstract is from feb 2019